PHARMACOLOGY HESI EXAM – COMPREHENSIVE STUDY GUIDE
(2026/2027 EDITION)
Unofficial original practice resource • 150 multiple-choice questions with rationales
IMPORTANT: This is not an official HESI, Elsevier, or NCSBN product. Items are original educational questions on standard nursing
pharmacology themes. Verify doses, black-box warnings, and guidelines with current drug references. For study only.
Section 1: Pharmacokinetics & Pharmacodynamics – ADME, Therapeutic Index, Receptor
Theory (20 questions)
Q1: A client takes a drug with extensive first-pass metabolism. Which route most avoids first-pass effect?
A. Oral tablet swallowed whole
B. Sublingual administration [CORRECT]
C. Enteric-coated oral capsule
D. Nasogastric tube to the stomach
Correct Answer: B
Rationale: Sublingual (and IV, IM, SL, rectal partially) bypasses hepatic first-pass. Swallowed oral routes undergo portal
circulation.
Q2: Protein-bound drugs are pharmacologically:
A. Active only while bound to albumin
B. Inactive while bound; the free fraction is active [CORRECT]
C. Unable to ever cause toxicity
D. Excreted only via bile as bound drug
Correct Answer: B
Rationale: Only unbound drug interacts with receptors. Displacement can raise free levels and toxicity.
Q3: A drug with a narrow therapeutic index means:
A. Toxic and therapeutic concentrations are close; monitoring is essential [CORRECT]
B. Overdose is almost impossible
C. No lab monitoring is ever needed
D. The drug has no adverse effects
Correct Answer: A
Rationale: NTI drugs (warfarin, digoxin, lithium, phenytoin) need careful dosing and often serum levels.
Q4: Half-life is the time required to:
A. Reach peak effect after one dose always
B. Reduce plasma concentration by 50% [CORRECT]
C. Completely eliminate the drug in 30 minutes for all drugs
D. Bind 100% of receptors
Correct Answer: B
Rationale: t½ is the time for plasma concentration to fall by half. Steady state is ~4–5 half-lives.
Q5: Steady state is typically reached after approximately:
A. 1 half-life
B. 4 to 5 half-lives [CORRECT]
C. 30 minutes for every drug
D. One year regardless of t½
Correct Answer: B
Rationale: About 4–5 half-lives to plateau with regular dosing.
Unofficial original practice bank • Not affiliated with HESI/Elsevier Page 1
, Q6: An agonist is a drug that:
A. Binds a receptor and produces a response [CORRECT]
B. Binds a receptor and blocks all response without any intrinsic activity
C. Has no receptor interaction
D. Only increases renal clearance
Correct Answer: A
Rationale: Agonists have affinity and intrinsic efficacy. Antagonists have affinity without efficacy.
Q7: A competitive antagonist:
A. Can be overcome by more agonist (surmountable) [CORRECT]
B. Destroys the receptor permanently in all cases
C. Never binds the same site as the agonist
D. Increases agonist potency
Correct Answer: A
Rationale: Competitive antagonists shift the dose-response curve right; more agonist can overcome them.
Q8: Potency vs efficacy: a more potent drug:
A. Produces a given effect at a lower dose [CORRECT]
B. Always has greater maximal effect (efficacy)
C. Is always safer
D. Cannot be an agonist
Correct Answer: A
Rationale: Potency is dose needed; efficacy is maximal effect. A less potent drug can be more efficacious.
Q9: CYP3A4 inhibition (e.g., grapefruit, ketoconazole) typically:
A. Decreases levels of CYP3A4 substrates
B. Increases levels of CYP3A4 substrates, raising toxicity risk [CORRECT]
C. Has no drug-interaction relevance
D. Only affects topical drugs
Correct Answer: B
Rationale: Inhibitors raise substrate concentrations. Inducers (rifampin, St. John’s wort) lower them.
Q10: A poor CYP2D6 metabolizer taking a prodrug like codeine may have:
A. Exaggerated morphine effect
B. Reduced conversion to morphine and less analgesia [CORRECT]
C. No change in any opioid effect ever
D. Automatic allergy to penicillin
Correct Answer: B
Rationale: Codeine needs CYP2D6 to morphine. Poor metabolizers get little effect; ultrarapid risk toxicity.
Q11: Renal impairment most directly affects:
A. Excretion of many hydrophilic drugs and active metabolites [CORRECT]
B. Only skin absorption of creams
C. Only the color of tablets
D. Gastric emptying exclusively
Correct Answer: A
Rationale: Reduce doses of renally cleared drugs (e.g., many antibiotics, lithium, gabapentin).
Unofficial original practice bank • Not affiliated with HESI/Elsevier Page 2
, Q12: Onset of action is:
A. Time from administration until the drug begins to produce an effect [CORRECT]
B. Identical to duration for all drugs
C. Always 8 hours
D. The time to complete elimination
Correct Answer: A
Rationale: Onset ≠ peak ≠ duration. Peak is maximum effect/concentration.
Q13: IV drugs have bioavailability of approximately:
A. 50%
B. 100% [CORRECT]
C. 0%
D. 10% always due to first-pass
Correct Answer: B
Rationale: IV bioavailability is 100% by definition (F=1).
Q14: Distribution across the blood–brain barrier is favored by:
A. Highly polar, large, protein-bound molecules
B. Lipophilic, small, unbound molecules [CORRECT]
C. All drugs equally
D. Only drugs given IM
Correct Answer: B
Rationale: CNS penetration prefers lipid solubility and low protein binding.
Q15: Loading dose is used to:
A. Rapidly achieve therapeutic concentration when t½ is long [CORRECT]
B. Replace all maintenance doses forever
C. Avoid all monitoring
D. Decrease volume of distribution
Correct Answer: A
Rationale: Loading dose ≈ Vd × desired concentration. Maintenance replaces what is cleared.
Q16: A partial agonist:
A. Produces less than maximal response even when receptors are occupied [CORRECT]
B. Is identical to a full inverse agonist always
C. Cannot bind receptors
D. Always causes more effect than a full agonist
Correct Answer: A
Rationale: Partial agonists (e.g., buprenorphine) have ceiling effect and can antagonize full agonists.
Q17: Tachyphylaxis is:
A. Rapid decrease in response after repeated doses [CORRECT]
B. A type of allergy only
C. Increased effect with each dose always
D. Renal failure
Correct Answer: A
Rationale: Acute tolerance (e.g., some nitrates, stimulants).
Unofficial original practice bank • Not affiliated with HESI/Elsevier Page 3
(2026/2027 EDITION)
Unofficial original practice resource • 150 multiple-choice questions with rationales
IMPORTANT: This is not an official HESI, Elsevier, or NCSBN product. Items are original educational questions on standard nursing
pharmacology themes. Verify doses, black-box warnings, and guidelines with current drug references. For study only.
Section 1: Pharmacokinetics & Pharmacodynamics – ADME, Therapeutic Index, Receptor
Theory (20 questions)
Q1: A client takes a drug with extensive first-pass metabolism. Which route most avoids first-pass effect?
A. Oral tablet swallowed whole
B. Sublingual administration [CORRECT]
C. Enteric-coated oral capsule
D. Nasogastric tube to the stomach
Correct Answer: B
Rationale: Sublingual (and IV, IM, SL, rectal partially) bypasses hepatic first-pass. Swallowed oral routes undergo portal
circulation.
Q2: Protein-bound drugs are pharmacologically:
A. Active only while bound to albumin
B. Inactive while bound; the free fraction is active [CORRECT]
C. Unable to ever cause toxicity
D. Excreted only via bile as bound drug
Correct Answer: B
Rationale: Only unbound drug interacts with receptors. Displacement can raise free levels and toxicity.
Q3: A drug with a narrow therapeutic index means:
A. Toxic and therapeutic concentrations are close; monitoring is essential [CORRECT]
B. Overdose is almost impossible
C. No lab monitoring is ever needed
D. The drug has no adverse effects
Correct Answer: A
Rationale: NTI drugs (warfarin, digoxin, lithium, phenytoin) need careful dosing and often serum levels.
Q4: Half-life is the time required to:
A. Reach peak effect after one dose always
B. Reduce plasma concentration by 50% [CORRECT]
C. Completely eliminate the drug in 30 minutes for all drugs
D. Bind 100% of receptors
Correct Answer: B
Rationale: t½ is the time for plasma concentration to fall by half. Steady state is ~4–5 half-lives.
Q5: Steady state is typically reached after approximately:
A. 1 half-life
B. 4 to 5 half-lives [CORRECT]
C. 30 minutes for every drug
D. One year regardless of t½
Correct Answer: B
Rationale: About 4–5 half-lives to plateau with regular dosing.
Unofficial original practice bank • Not affiliated with HESI/Elsevier Page 1
, Q6: An agonist is a drug that:
A. Binds a receptor and produces a response [CORRECT]
B. Binds a receptor and blocks all response without any intrinsic activity
C. Has no receptor interaction
D. Only increases renal clearance
Correct Answer: A
Rationale: Agonists have affinity and intrinsic efficacy. Antagonists have affinity without efficacy.
Q7: A competitive antagonist:
A. Can be overcome by more agonist (surmountable) [CORRECT]
B. Destroys the receptor permanently in all cases
C. Never binds the same site as the agonist
D. Increases agonist potency
Correct Answer: A
Rationale: Competitive antagonists shift the dose-response curve right; more agonist can overcome them.
Q8: Potency vs efficacy: a more potent drug:
A. Produces a given effect at a lower dose [CORRECT]
B. Always has greater maximal effect (efficacy)
C. Is always safer
D. Cannot be an agonist
Correct Answer: A
Rationale: Potency is dose needed; efficacy is maximal effect. A less potent drug can be more efficacious.
Q9: CYP3A4 inhibition (e.g., grapefruit, ketoconazole) typically:
A. Decreases levels of CYP3A4 substrates
B. Increases levels of CYP3A4 substrates, raising toxicity risk [CORRECT]
C. Has no drug-interaction relevance
D. Only affects topical drugs
Correct Answer: B
Rationale: Inhibitors raise substrate concentrations. Inducers (rifampin, St. John’s wort) lower them.
Q10: A poor CYP2D6 metabolizer taking a prodrug like codeine may have:
A. Exaggerated morphine effect
B. Reduced conversion to morphine and less analgesia [CORRECT]
C. No change in any opioid effect ever
D. Automatic allergy to penicillin
Correct Answer: B
Rationale: Codeine needs CYP2D6 to morphine. Poor metabolizers get little effect; ultrarapid risk toxicity.
Q11: Renal impairment most directly affects:
A. Excretion of many hydrophilic drugs and active metabolites [CORRECT]
B. Only skin absorption of creams
C. Only the color of tablets
D. Gastric emptying exclusively
Correct Answer: A
Rationale: Reduce doses of renally cleared drugs (e.g., many antibiotics, lithium, gabapentin).
Unofficial original practice bank • Not affiliated with HESI/Elsevier Page 2
, Q12: Onset of action is:
A. Time from administration until the drug begins to produce an effect [CORRECT]
B. Identical to duration for all drugs
C. Always 8 hours
D. The time to complete elimination
Correct Answer: A
Rationale: Onset ≠ peak ≠ duration. Peak is maximum effect/concentration.
Q13: IV drugs have bioavailability of approximately:
A. 50%
B. 100% [CORRECT]
C. 0%
D. 10% always due to first-pass
Correct Answer: B
Rationale: IV bioavailability is 100% by definition (F=1).
Q14: Distribution across the blood–brain barrier is favored by:
A. Highly polar, large, protein-bound molecules
B. Lipophilic, small, unbound molecules [CORRECT]
C. All drugs equally
D. Only drugs given IM
Correct Answer: B
Rationale: CNS penetration prefers lipid solubility and low protein binding.
Q15: Loading dose is used to:
A. Rapidly achieve therapeutic concentration when t½ is long [CORRECT]
B. Replace all maintenance doses forever
C. Avoid all monitoring
D. Decrease volume of distribution
Correct Answer: A
Rationale: Loading dose ≈ Vd × desired concentration. Maintenance replaces what is cleared.
Q16: A partial agonist:
A. Produces less than maximal response even when receptors are occupied [CORRECT]
B. Is identical to a full inverse agonist always
C. Cannot bind receptors
D. Always causes more effect than a full agonist
Correct Answer: A
Rationale: Partial agonists (e.g., buprenorphine) have ceiling effect and can antagonize full agonists.
Q17: Tachyphylaxis is:
A. Rapid decrease in response after repeated doses [CORRECT]
B. A type of allergy only
C. Increased effect with each dose always
D. Renal failure
Correct Answer: A
Rationale: Acute tolerance (e.g., some nitrates, stimulants).
Unofficial original practice bank • Not affiliated with HESI/Elsevier Page 3
